R21/Matrix-M
Phase 3Biologic
R21/Matrix-M is one of 26 biologic programs targeting Malaria. It is currently in Phase 3.
1
Indications
6
Total Trials
2
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
94 competitors in Malaria
#DrugCompanyPhaseTrials
1Dihydroartemisinin-Piperaquine
GSKPhase 3
Rabies Vaccine
NovartisPhase 3
YF-Vax
SanofiPhase 3
Krintafel
GGlaxo Dba Glaxosmithkline
Phase 3
Artemether-Lumefantrine (AL)
NovartisPhase 3
Artesunate-Amodiaquine
SanofiPhase 3
R21/Matrix-M
UUniversity of Oxford
Phase 3
Pyramax
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Measles
GSKPhase 2
Biltricide
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malaria4 trials
Show 1 more trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R21/Matrix-M. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Oxford